drugset / Trial / NCT03009292

Pharmacokinetic Study of E7080/Lenvatinib in Chinese Subjects With Solid Tumor

NCT03009292

Phase 1 Completed 12 enrolled Eisai Inc.
NaSingle-groupOpen-labelTreatment

Summary

Study E7080-C086-108 is an open-label, single- and multiple-dose pharmacokinetic (PK) study of lenvatinib (administered orally, once a day \[QD\]) in Chinese participants with solid tumor. A total of 12 participants will be enrolled to evaluate the PK of 24 milligrams (mg) QD dosing of lenvatinib.

Timeline

Start
2018-08-06
Primary completion
2018-12-24
Completion
2021-08-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Lenvatinib Small molecule 24 mg Oral

Indications